Compare LENZ & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LENZ | BNR |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.4M | 252.7M |
| IPO Year | 2021 | 2019 |
| Metric | LENZ | BNR |
|---|---|---|
| Price | $9.97 | $21.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $45.60 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 32.9K |
| Earning Date | 05-06-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,088,000.00 | N/A |
| Revenue This Year | $51.35 | $111.65 |
| Revenue Next Year | $198.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $2.18 |
| 52 Week High | $50.19 | $41.72 |
| Indicator | LENZ | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 55.95 |
| Support Level | $8.99 | $19.72 |
| Resistance Level | $10.29 | $23.42 |
| Average True Range (ATR) | 0.68 | 1.43 |
| MACD | 0.25 | 0.91 |
| Stochastic Oscillator | 87.82 | 81.30 |
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.